HSCS
HeartSciences Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- X Aug 14 Short interest falls 33.3% to 50.7K
- X Aug 31 Short interest jumps 125.2% to 114.2K
- X Sep 15 Short interest falls 65.1% to 39.9K
- R Sep 17 HeartSciences Inc. filed this DEFA14A to furnish a press release fro…
- R Sep 25 HeartSciences Inc. filed a universal shelf registration statement on…
- X Sep 30 Short interest falls 29.9% to 27.9K
- R Oct 19 HeartSciences Inc. (HSCS) is seeking shareholder approval at a Novem…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 0 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.695 → −$0.620 over 90 days. 1 up, 0 down in 30 days.
- TrendDOWNTREND
10% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| OSAIC HOLDINGS, INC. | DOUBLED | $1.6K |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $83.2K |
| BANK OF AMERICA CORP /DE/ | ADD | $80.00 |
| Federation des caisses Desjardins du Quebec | ADD | $2.4K |
| BANK OF AMERICA CORP /DE/ | ADD | $66.00 |
| UBS Group AG | DOUBLED | $7.4K |
| UBS Group AG | ADD | $5.0K |
| BANK OF AMERICA CORP /DE/ | ADD | $34.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Mar 2026Price is below the lowest target. Median implies +277%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Mar 24, 2026 | Ascendiant Capital MAINTAIN | Buy |
| Dec 22, 2025 | Ascendiant Capital MAINTAIN | Buy |
| Oct 1, 2025 | Ascendiant Capital MAINTAIN | Buy |
| Mar 18, 2025 | Ascendiant Capital MAINTAIN | Buy |
| Dec 18, 2024 | Maxim Group REITERATE | Buy |
| Sep 23, 2024 | Ascendiant Capital REITERATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jul 7, 2026 | Watson Danielle See Remarks | AWARD | 25,000 sh |
| Jun 22, 2026 | Simpson Andrew See Remarks | AWARD | 425,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.62 | -$0.62–-$0.62 | +4.6% | $0.00 |
| Next Q | -$0.61 | -$0.61–-$0.61 | +7.6% | $5.0K |
| Current FY | -$2.46 | -$2.46–-$2.46 | +6.1% | $17.1K |
| Next FY | -$1.75 | -$1.75–-$1.75 | +5.9% | $3.1M |
Short side
FINRA· Oct 15, 2026SecBot reports
50 filings · 1 press release · 3 bullish · 4 bearish · 5 mixed · 38 neutral- NEUTRAL DEFA14AOct 26, 2026
HeartSciences filed a DEFA14A containing solicitation materials related to its pending all-stock merger with Fortitude Mining Holdings, Inc., including social media posts by a DCG executive. The filing is routine additional proxy solicitation material and does not contain new financial terms or…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL DEFA14AOct 26, 2026
HeartSciences filed definitive additional proxy materials (DEFA14A) in connection with its proposed all-stock merger with Fortitude Mining Holdings, Inc., a Zcash-focused crypto mining platform. The filing includes a social media post from a Digital Currency Group executive and provides standard…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13D/AOct 23, 2026
CEO Andrew Simpson filed an amended Schedule 13D disclosing unchanged beneficial ownership of…
Monitor the shareholder vote on the Fortitude Mining merger — the CEO's 7.5% stake and insider alignment are relevant to deal approval odds. The FDA clearance is a positive standalone catalyst but…
- NEUTRAL DEFA14AOct 21, 2026
HeartSciences Inc. filed a DEFA14A providing additional soliciting materials in connection with…
Monitor shareholder vote outcome and any additional proxy solicitation materials. The merger represents a fundamental business transformation from medtech to crypto mining — watch for any dissident…
All HSCS filing & press-release reports (51)
- DEFA14A reportOct 26, 2026
- DEFA14A reportOct 26, 2026
- SC 13D/A reportOct 23, 2026
- DEFA14A reportOct 21, 2026
- DEFA14A reportOct 19, 2026
- DEFA14A reportOct 19, 2026
- DEFM14A reportOct 19, 2026
- DEFA14A reportOct 15, 2026
- 424B5 reportOct 9, 2026
- DEFA14A reportOct 6, 2026
- 8-K reportOct 6, 2026
- DEFA14A reportOct 6, 2026
- DEFA14A reportOct 2, 2026
- 8-K reportOct 2, 2026
- DEFA14A reportSep 30, 2026
- S-3 reportSep 25, 2026
- DEFA14A reportSep 21, 2026
- DEFA14A reportSep 18, 2026
- DEFA14A reportSep 17, 2026
- DEFA14A reportSep 17, 2026
- 8-K reportSep 17, 2026
- DEFA14A reportSep 16, 2026
- DEFA14A reportSep 15, 2026
- 8-K reportSep 15, 2026
- PRESS-RELEASE reportSep 15, 2026
- DEFA14A reportSep 11, 2026
- DEFA14A reportSep 10, 2026
- DEFA14A reportSep 10, 2026
- DEFA14A reportSep 8, 2026
- DEFA14A reportSep 9, 2026
- DEFA14A reportSep 4, 2026
- DEFA14A reportSep 4, 2026
- DEFA14A reportSep 3, 2026
- DEFA14A reportSep 2, 2026
- DEFA14A reportAug 31, 2026
- DEFA14A reportAug 28, 2026
- DEFA14A reportAug 25, 2026
- DEFA14A reportAug 24, 2026
- DEFA14A, 8-K reportAug 20, 2026
- DEFA14A, 8-K reportAug 7, 2026
- DEFA14A reportAug 6, 2026
- DEFA14A reportJul 29, 2026
- PRESS-RELEASE reportJul 29, 2026
- 8-K reportJul 29, 2026
- PRESS-RELEASE reportJul 23, 2026
- DEFA14A reportJul 10, 2026
- 8-K reportJul 10, 2026
- 8-K reportJun 26, 2026
- DEFA14A reportJun 26, 2026
- DEFA14A reportJun 26, 2026
- PRESS-RELEASE reportMar 16, 2026